Moderna files for full U.S. approval of COVID-19 vaccine

Video Credit: Reuters - Politics
Published on June 1, 2021 - Duration: 01:04s

Moderna files for full U.S. approval of COVID-19 vaccine

Moderna on Tuesday filed for full U.S. approval of its COVID-19 vaccine, becoming the second drugmaker to do so after Pfizer and its German partner BioNTech sought full clearance for their vaccine last month.

This report produced by Freddie Joyner.


Moderna files for full U.S. approval of COVID-19 vaccine

Moderna on Tuesday filed for full U.S. approval of its COVID-19 vaccine, making it the second drugmaker in the country to do so.

Currently, the company is only authorized for emergency use in the U.S., but a full approval could be an important step in diminishing vaccine hesitancy.

It would also allow the vaccine maker to market their shots directly, as well as help companies and government agencies looking for vaccinations for their employees.

The move by Moderna comes just weeks after rival Pfizer and its German partner BioNTech sought full approval for their COVID-19 vaccine in the United States.

Moderna has an agreement with the U.S. government to supply 300 million doses of its COVID-19 vaccine with more than 151 million doses already distributed.

The company said it will continue to submit data to the U.S. Food and Drug Administration on a rolling basis over the coming weeks with a request for a priority review.

On completion of the submission, the FDA will notify the company when it is formally accepted for review.

You are here


💡 newsR Knowledge: Other News Mentions


BioNTech

German biotechnology company
The German pharmaceutical group behind one of the most successful COVID-19 vaccines wants to use the same technology to develop a malaria vaccine. 
2 days ago • Sky News
This is the second vaccine approved for use on children in Europe. The first vaccine by Pfizer/BioNTech was approved in May.
Credit: DNA - Published 5 days ago


Pfizer

American multinational pharmaceutical corporation
An eight-week gap between the two doses of the Pfizer vaccine is a "sweet spot", according to new research.
6 days ago • Sky News

Related videos from verified sources

Moderna And Pfizer To Expand COVID Vaccine Trials For Young Children 00:23
Video credit: WBZ CBS Boston - Published 1 day ago 

Why haven't COVID-19 vaccines gotten full approval yet? 02:57
Video credit: KTNV Channel 13 Las Vegas - Published 2 days ago 

Canadian Government Announces Plan to Reopen Borders 01:40
Video credit: Wibbitz Top Stories - Published 1 week ago 

You might like